secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001213900-24-071061
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed confirms INM-901 oral formulation for Alzheimer's; bioavailability comparable to injection
--------------------------------------------------------------------------------

- Preclinical data show oral INM-901 achieves similar brain drug levels as intraperitoneal (IP) injection over 24h.
- Oral delivery offers potential advantages over IV large-molecule antibody therapies, including lower cost and easier access.
- INM-901 is a proprietary small molecule that crosses the blood-brain barrier via GI absorption.
- Company conducting CMC, drug metabolism, dose-ranging, and PK studies to support IND submission.
- Current disease-modifying Alzheimer's treatments require IV infusion every 2-4 weeks at medical facilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/0001213900-24-071061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/ea0211922-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-071061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer